- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of bimekizumab.
Moderate to severe plaque psoriasis
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of plaque psoriasis.
320mg (2 injections of 160mg) at week 0, 4, 8, 12, 16 and every 8 week thereafter.
Consider discontinuation of treatment in patients who show no response after 16 weeks of treatment.
Additional Dosage Information
For patients with a bodyweight greater than or equal to 120kg and who did not achieve complete skin clearance at week 16, 320mg every 4 weeks after week 16 may further improve treatment response.
For subcutaneous injection only.
Bimekizumab is administered into the thigh, abdomen and upper arm.
Children under 18 years
Precautions and Warnings
Females of childbearing potential
History of recurrent infection
Inflammatory bowel disease
Latent or healed tuberculosis
Administration of live vaccines is not recommended
Consider prophylactic anti-tuberculosis therapy if appropriate
Prior to starting therapy screen for latent tuberculosis
Treat and control infections prior to commencing therapy
Treatment to be initiated and supervised by a specialist
Avoid injection into broken or bruised skin
For subcutaneous use only
Record name and batch number of administered product
Self-admin. - only if adequately trained and have access to expert advice
Vary injection site during prolonged therapy
Discontinue if signs and symptoms of inflammatory bowel disease occur
Monitor patient for signs of serious infection
Advise patient to report symptoms of infection immediately
Risk of developing opportunistic infections
Discontinue if allergic reaction occurs
Discontinue if no response to treatment after 16 weeks
Interrupt treatment if severe infection develops
Female: Contraception required during and for 17 weeks after treatment
Pregnancy and Lactation
Bimekizumab is contraindicated during pregnancy.
The manufacturer recommends that it is preferable to avoid the use of bimekizumab during pregnancy. There is limited data regarding the use of bimekizumab. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development.
Bimekizumab is contraindicated during breastfeeding.
The manufacturer advises that the patient either discontinues breastfeeding or discontinues bimekizumab. It is unknown whether bimekizumab is excreted in human breast milk. A risk to the infant cannot be excluded.
Candidiasis (mouth or throat)
Inflammatory bowel disease
Injection site reactions
Upper respiratory tract infection
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: October 2021
Summary of Product Characteristics: Bimzelx 160mg solution for injection in pre-filled pen. UCB Pharma Limited. Revised August 2021.
Summary of Product Characteristics: Bimzelx 160mg solution for injection in pre-filled syringe. UCB Pharma Limited. Revised August 2021.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.